Pulse BiosciencesPLSE +3.27%31 5-Year Yield-on-Cost % is 0.00 as of Jul. 05, 2026. GuruFocus rates PLSE with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 328 Medical Devices & Instruments companies, Pulse Biosciences ranks worse than 304877.74% on this metric.
Pulse Biosciences's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Pulse Biosciences's 5-Year Yield-on-Cost % or its related term are showing as below:
PLSE's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.325 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Pulse Biosciences 5-Year Yield-on-Cost % Related Terms
PLSE vs LMAT, XRAY, KMTS: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Pulse Biosciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulse Biosciences 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Pulse Biosciences's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Pulse Biosciences (PLSE) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pulse Biosciences and its competitors. According to the industry distribution chart, Pulse Biosciences ranks #999999 out of 328 companies in the Medical Devices & Instruments industry.
Is Pulse Biosciences' 5-Year Yield-on-Cost % too high?
Pulse Biosciences' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Pulse Biosciences ranks #999999 out of 328 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Pulse Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pulse Biosciences' 5-Year Yield-on-Cost % compare to LMAT and XRAY?
According to the Medical Devices & Instruments industry distribution chart, Pulse Biosciences ranks #999999 out of 328 companies for 5-Year Yield-on-Cost %. This places Pulse Biosciences in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.33, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pulse Biosciences and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulse Biosciences's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulse Biosciences stock overvalued right now?
Pulse Biosciences (PLSE) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Pulse Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Pulse Biosciences (PLSE), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
31GF Score
Get the complete analysis for PLSE
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSE has been successfully added to your 